Author's reply: Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis.
作者信息
Konta Yusuke, Saito Eiichiro, Sato Koji, Furuta Kyohei, Miyauchi Kenichiro, Furukawa Akiko, Sato Hiroshi, Yamamoto Tae
机构信息
Department of Internal Medicine, Sendai City Hospital, Japan.
Department of Nephrology, JR Sendai Hospital, Japan.
出版信息
Intern Med. 2023 Mar 1;62(5):819. doi: 10.2169/internalmedicine.0341-22. Epub 2022 Jul 22.
Abstract
摘要
相似文献
1
Author's reply: Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis.作者回复：钠-葡萄糖协同转运蛋白2抑制剂与肾小管间质性肾炎之间的详细因果关系。
Intern Med. 2023 Mar 1;62(5):819. doi: 10.2169/internalmedicine.0341-22. Epub 2022 Jul 22.
2
Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis.钠-葡萄糖协同转运蛋白2抑制剂与肾小管间质性肾炎之间的详细因果关系
Intern Med. 2023 Mar 1;62(5):817. doi: 10.2169/internalmedicine.0124-22. Epub 2022 Jul 22.
3
Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor.使用钠-葡萄糖共转运蛋白 2 抑制剂后发生的肾小管间质性肾炎。
Intern Med. 2022 Nov 1;61(21):3239-3243. doi: 10.2169/internalmedicine.9011-21. Epub 2022 Mar 12.
4
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.钠葡萄糖协同转运蛋白2抑制剂恩格列净可独立于钠葡萄糖协同转运蛋白2减少梗死面积。
Circulation. 2023 Jan 17;147(3):276-279. doi: 10.1161/CIRCULATIONAHA.122.061688.
5
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂恩格列净在肾功能损害受试者中的药代动力学、药效学及安全性
Diabetes Obes Metab. 2014 Mar;16(3):215-22. doi: 10.1111/dom.12182. Epub 2013 Aug 19.
6
Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.恩格列净，一种钠-葡萄糖协同转运蛋白2抑制剂，对实验性糖尿病肾病发挥抗炎和抗纤维化作用，部分是通过抑制晚期糖基化终末产物受体轴实现的。
Horm Metab Res. 2015 Aug;47(9):686-92. doi: 10.1055/s-0034-1395609. Epub 2015 Jan 22.
7
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.新型选择性钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂恩格列净控制血糖，可改善肥胖和2型糖尿病小鼠的心血管损伤及认知功能障碍。
Cardiovasc Diabetol. 2014 Oct 26;13:148. doi: 10.1186/s12933-014-0148-1.
8
Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?SGLT2 抑制对人近端肾小管细胞的影响——在糖尿病肾病中的肾脏保护作用？
PLoS One. 2013;8(2):e54442. doi: 10.1371/journal.pone.0054442. Epub 2013 Feb 4.
9
Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.托格列净是一种钠-葡萄糖协同转运蛋白2的选择性抑制剂，可抑制KKAy/Ta小鼠（肥胖型2型糖尿病动物）的肾脏损伤。
Diab Vasc Dis Res. 2016 Nov;13(6):438-441. doi: 10.1177/1479164116657304. Epub 2016 Jul 12.
10
Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病患者安全性的最新综述
Expert Opin Drug Saf. 2016 Oct;15(10):1401-12. doi: 10.1080/14740338.2016.1216100. Epub 2016 Aug 12.
本文引用的文献
1
Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor.使用钠-葡萄糖共转运蛋白 2 抑制剂后发生的肾小管间质性肾炎。
Intern Med. 2022 Nov 1;61(21):3239-3243. doi: 10.2169/internalmedicine.9011-21. Epub 2022 Mar 12.
2
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.CREDENCE试验的见解表明，在使用卡格列净治疗期间，估计肾小球滤过率急剧下降，这对临床实践具有重要意义。
Kidney Int. 2021 Apr;99(4):999-1009. doi: 10.1016/j.kint.2020.10.042. Epub 2020 Dec 11.
3
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.1 型糖尿病患者钠-葡萄糖共转运蛋白 2 抑制剂的肾脏血流动力学效应。
Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. Epub 2013 Dec 13.
Zotero 插件